GentiBio could earn $1.9 billion under IBD deal with BMS

Boston, USA-based engineered regulatory T cells (Tregs) company GentiBio has entered into a collaboration with US pharma major Bristol Myers Squibb (NSE: BMY) to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD).

The collaboration brings together GentiBio’s proprietary engineered Treg platform for generating scalable, stable, highly-selective, and durable Tregs with Bristol Myers’ leadership in cell therapies and immunology.

GentiBio launched two years ago, with $20 million seed funding from OrbiMed, Novartis Venture Fund and RA Capital Management. In August last year GentiBio also announced it has closed on a Series A financing generating immediate proceeds of $157 million.